The impact of the TailorX and RxPonder studies and the use of Oncotype Dx in clinical practice: A single Breast Cancer Center experience

被引：0
|
作者：
Nasikas, D. [1 ]
Fostira, F. [2 ]
Tsoulos, N. [3 ]
Fokianou, A. [1 ]
Kontogianni, P. [1 ]
Ntasiou, P. [1 ]
Xepapadakis, G. [1 ]
机构：
[1] IASO Hosp, Breast Clin 2, Athens, Greece
[2] NCSR DEMOCRITOS, Mol Diagnost Lab, Athens, Greece
[3] Genekor Med SA, Athens, Greece
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P152
引用
收藏
页码：S75 / S75
页数：1
相关论文
共 50 条
  • [21] Clinical Impact of a Novel Model Predictive of Oncotype DX Recurrence Score in Breast Cancer
    Yamamoto, Shinya
    Chishima, Takashi
    Shibata, Yukako
    Harada, Fumi
    Takeuchi, Hideki
    Yamada, Akimitsu
    Narui, Kazutaka
    Misumi, Toshihiro
    Ishikawa, Takashi
    Endo, Itaru
    IN VIVO, 2021, 35 (04): : 2439 - 2444
  • [22] Treatment pattern of early-stage premenopausal breast cancer patients with low Oncotype DX score: Single center experience
    Al Saheli, Zaid Ihab
    Ammari, Omar
    Albusoul, Linda
    Dabak, Vrushali S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] ONCOTYPE DX® - THE SiRIO-LIBANeS HOSPITAL CANCER CENTER EXPERIENCE
    Pereira, A. A. L.
    Shimada, A. K.
    Santini, F. C.
    Nascimento, E. C.
    Ribeiro, K. B.
    Marques, R. J.
    Mano, M. S.
    Katz, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 112
  • [24] Current controversies in the use of Oncotype DX in early breast cancer
    Giachetti, Pier Paolo M. Berton
    Schianca, Ambra Carnevale
    Trapani, Dario
    Marra, Antonio
    Toss, Angela
    Marchio, Caterina
    Dieci, Maria Vittoria
    Gentilini, Oreste Davide
    Criscitiello, Carmen
    Kalinsky, Kevin
    Sparano, Joseph A.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2025, 135
  • [25] The Impact of Oncotype DX in invasive lobular carcinoma of the breast: An institutional experience
    McGreevy, Christopher
    Mateo, Alina
    De La Cruz, Lucy
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 270 - 270
  • [26] A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center
    Liang, H.
    Brufsky, A. M.
    Lembersky, B. B.
    Rastogi, P.
    Vogel, V. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S105 - S105
  • [27] Who Is Receiving the Oncotype Dx Breast Cancer Assay in Current Practice?
    Hosseini, Ava
    Baker, Jennifer L.
    Tokin, Christopher
    Mailey, Brian
    Wallace, Anne M.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 59 - 59
  • [28] Oncotype Dx in Node-negative Breast Cancer: Our Experience
    Rizvi, S. A. J.
    Eldeeb, H.
    Soulsby, R.
    Taylor, A.
    Karina, M.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E113 - E113
  • [29] Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
    Orucevic, A.
    McNeil, M. L.
    Bell, J. L.
    McNabb, A. P.
    Heidel, R. E.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
    Orucevic, Amila
    Bell, John L.
    King, Megan
    McNabb, Alison P.
    Heidel, Robert E.
    BREAST, 2019, 46 : 116 - 125
12345